Abbott Laboratories

Abbott Laboratories announced strong second-quarter 2026 financial results, with reported sales up 13.0% and comparable sales up 4.8%, while raising its full-year adjusted diluted EPS guidance.

Abbott Laboratories shareholders approved the 2026 Incentive Stock Program, replacing the 2017 program, and the board size was increased to thirteen directors.

Abbott Laboratories has reached a proposed settlement in a consolidated shareholder derivative lawsuit regarding infant formula manufacturing and oversight.

Abbott Laboratories reported Q1 2026 results and confirmed the completion of its acquisition of Exact Sciences, while providing updated full-year guidance.

Abbott Laboratories has finalized its acquisition of Exact Sciences, expanding its leadership in cancer screening and diagnostics.

Abbott Laboratories announced a $20 billion senior notes offering to finance its acquisition of Exact Sciences Corporation and for general corporate purposes.

Abbott Laboratories reported strong Q2 2026 results, with net sales increasing 13.0% to $12.59 billion, largely driven by the recent acquisition of Exact Sciences.

Abbott Laboratories reported a 6.9% increase in net sales for the third quarter of 2025, driven by robust performance in its Medical Devices segment, despite a decline in COVID-19 testing sales.

Abbott Laboratories reported robust second-quarter 2025 financial results, with net sales increasing 7.4% and diluted EPS rising 36.5%, primarily fueled by strong performance in its Medical Devices segment.

Abbott Laboratories announces increased net sales and earnings for the first quarter of 2025, driven by growth in Medical Devices, Established Pharmaceutical Products, and Nutritional Products.

Abbott Laboratories' third-quarter results show a 7.4% increase in sales excluding foreign exchange impacts, driven by growth in medical devices and established pharmaceuticals, despite a decline in COVID-19 testing revenue.

Abbott Laboratories' second quarter results show a 4% increase in sales, driven by strong performance in Medical Devices and Nutritional Products, despite a decline in COVID-19 testing revenue.

Abbott Laboratories' 2024 10-K filing reveals revenue growth driven by Medical Devices, Established Pharmaceuticals, and Nutritional Products, despite a decline in COVID-19 testing-related sales.

Abbott Laboratories has entered into a new five-year credit agreement for $5 billion, replacing its previous facility and bolstering its financial position.

Abbott Laboratories Director John G. Stratton reported a transaction involving stock equivalent units on June 30, 2026.

Michael F. Roman, a Director at Abbott Laboratories, acquired stock equivalent units valued at $90.74 per unit on June 30, 2026, as reported in a Form 4 filing.

Abbott Laboratories Director Patricia Paola Gonzalez reported transactions involving stock equivalent units, reflecting director fees and dividend reinvestment.

Kevin T. Conroy, a Director at Abbott Laboratories, reported the acquisition of 231 stock equivalent units on June 30, 2026, valued at $90.74 per unit.

Nita Ahuja, a Director at Abbott Laboratories, reported transactions involving stock equivalent units, reflecting her compensation and investment in the company.

Louis H. Morrone, Executive Vice President at Abbott Laboratories, reported a transaction involving the sale of common shares.

Abbott Laboratories announces its 2026 Annual Meeting of Shareholders, detailing director elections, executive compensation, and equity plan approvals, while reporting strong 2025 total shareholder return.

Abbott Laboratories announces its annual shareholder meeting to be held virtually on April 25, 2025, with key items including the election of directors, ratification of auditors, and an advisory vote on executive compensation.

Abbott Laboratories' 2025 proxy statement details the election of directors, executive compensation, corporate governance, and sustainability initiatives, highlighting strong shareholder returns and a commitment to long-term growth.

Abbott Laboratories will hold its annual shareholder meeting virtually on April 26, 2024, to vote on the election of directors, ratification of auditors, and executive compensation.

Abbott Laboratories' 2024 proxy statement details the company's executive compensation program, corporate governance practices, and shareholder engagement efforts, highlighting a commitment to aligning executive pay with company performance and shareholder returns.

Vanguard Capital Management has reported beneficial ownership of 130,676,776 shares, representing 7.5% of Abbott Laboratories' common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Abbott Laboratories, reporting 0% beneficial ownership following an internal realignment.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 10.05% beneficial ownership stake in Abbott Laboratories common stock.